Sign inJoin waitlistJoin the waitlist

Nazanin Majd

Director, Clinical Research · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Clinical Research · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2017–2019
Neurology
Texas Tech University Health Sciences Center at Lubbock
2012–2014
Icahn School of Medicine at Mount Sinai
2011–2012
Texas Tech University Health Sciences Center School of Medicine
2007–2011

Research

Molecular Mechanisms of Treatment Resistance in Glioblastoma
Review · International Journal of Molecular Sciences · 2020 · Last of 3 authors · Corresponding · 232 citations
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma
Nature Cell Biology · 2019 · 146 citations
HDAC4 inhibits cell-cycle progression and protects neurons from cell death
Developmental Neurobiology · 2008 · First of 6 authors · 122 citations

John de Groot
21 papers
Carlos Matsuoka
10 papers
Barbara O'Brien
8 papers
Marta Penas-Prado
8 papers
Vinay Puduvalli
8 papers
Debra Yeboa
7 papers
Gregory Fuller
7 papers
Susan McGovern
7 papers
Arnold Paulino
6 papers
Jason Huse
6 papers
Pushan Dasgupta
6 papers · 6 as a fellow
Ashley Aaroe
5 papers · 1 as a fellow

Grants

SPORE in Brain Cancer
National Cancer Institute · P50
Project lead · $853.4K · University of Tx Md Anderson Can Ctr
2008–2029

Clinical trials

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Principal investigator · Recruiting · Early phase 1
M.D. Anderson Cancer Center
2023–2027
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2020–2027